A significantly lower proportion of Hispanic and Black women who underwent screening received 3D mammograms, according to a new study presented at the 2022 San Antonio Breast Cancer Symposium.
Columbia’s cell therapy lab, which creates customized cell therapies, is testing its first product, T cells trained to fight dangerous infections in transplant patients.
A recent rise in a rare lymphoma has been linked to breast implants, but Columbia researchers have found that the risk is extremely low among women who have reconstructive surgery after mastectomy.
Breast cancer survival has improved by about 40% since the 1980s. Columbia oncologist Katherine Crew discusses how new genetic tests, treatments, and screening methods should further improve survival.
Columbia is one of the few places in the world where scientists can research an emerging radiotherapy technique called FLASH, which could drastically shorten radiation treatment for cancer patients.
Velocity, Columbia’s annual fundraiser for cancer research, has changed this year, with participants cycling, running, and even sailing to support cancer research and care.
The Herbert Irving Comprehensive Cancer Center has been redesignated as a Comprehensive Cancer Center by the NCI, the federal government’s principal agency for cancer research, care, and training.
A study of cancer patients with COVID-19 finds mortality is significantly higher than in the general population and Black patients are half as likely to receive the antiviral remdesivir.
Compared to yearly screening, more frequent mammograms for women treated for early-stage breast cancer did not confer additional benefit, a study from Columbia University oncologists has found.
Seizures are usually considered a side effect of brain cancer, but a new Columbia University study of mice suggests they may also fuel the further growth of brain tumors.
Columbia University President Lee Bollinger announced the appointment of Anil Rustgi, MD, director of the Herbert Irving Comprehensive Cancer Center, as interim EVP and dean, effective July 1, 2020.
Scientists at Columbia's Herbert Irving Comprehensive Cancer Center are using technologies developed to study cancer to look for drugs to treat COVID-19 and disarm the virus.